Robert Ward Net Worth

The estimated Net Worth of Robert Ward is at least $74.9 Thousand dollars as of 29 February 2020. Mr. Ward owns over 76,806 units of OncoSec Medical Inc stock worth over $74,915 and over the last 10 years he sold ONCS stock worth over $0. In addition, he makes $0 as Independent Director at OncoSec Medical Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Ward ONCS stock SEC Form 4 insiders trading

Robert has made over 12 trades of the OncoSec Medical Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 76,806 units of ONCS stock worth $21,506 on 29 February 2020.

The largest trade he's ever made was exercising 213,595 units of OncoSec Medical Inc stock on 26 December 2018 worth over $59,807. On average, Robert trades about 23,705 units every 82 days since 2014. As of 29 February 2020 he still owns at least 267,552 units of OncoSec Medical Inc stock.

You can see the complete history of Mr. Ward stock trades at the bottom of the page.

Robert Ward biography

Robert E. Ward serves as Independent Director of the Company. He is currently the Chief Executive Officer and Chairman of the Board of Eloxx Pharmaceuticals, Inc., roles he has held since December 2017. He was a Director and Chair of the Governance Committee of Akari Therapeutics from October 2016 to August 2018. Mr. Ward previously served as the Chief Executive Officer, President and member of the board of directors at Radius Health, Inc. from December 2013 to July 2017. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of AstraZeneca from 2011 to December 2013. He has held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward has been a Director of Akari Therapeutics, Plc since October 2016. Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, a M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from The Johns Hopkins University School of Medicine.

How old is Robert Ward?

Robert Ward is 62, he's been the Independent Director of OncoSec Medical Inc since 2018. There are 1 older and 9 younger executives at OncoSec Medical Inc. The oldest executive at OncoSec Medical Inc is Margaret Dalesandro, 73, who is the Independent Chairman of the Board.

What's Robert Ward's mailing address?

Robert's mailing address filed with the SEC is 24, North Main Street, Pennington, Mercer County, New Jersey, 08534, United States of America.

Insiders trading at OncoSec Medical Inc

Over the last 12 years, insiders at OncoSec Medical Inc have traded over $1,474,366 worth of OncoSec Medical Inc stock and bought 9,275,650 units worth $39,853,210 . The most active insiders traders include Grand Pharmaceutical & Heal..., Holdings, Inc. Alpha, and Robert Ward. On average, OncoSec Medical Inc executives and independent directors trade stock every 62 days with the average trade being worth of $51,563. The most recent stock trade was executed by Robert J Del Aversano on 9 February 2023, trading 40 units of ONCS stock currently worth $55.

What does OncoSec Medical Inc do?

oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar

Complete history of Mr. Ward stock trades at OncoSec Medical Inc, Radius Recycling, and Eloxx Pharmaceuticals Inc

OncoSec Medical Inc executives and stock owners

OncoSec Medical Inc executives and other stock owners filed with the SEC include:

• Daniel O'Connor,
  President, Chief Executive Officer, Director
• Robert J. DelAversano CPA,
  VP of Fin. and Principal Accounting Officer & Controller
• Margaret Dalesandro,
  Independent Chairman of the Board
• Herbert Lyerly,
  Independent Director
• Chao Zhou,
  Director
• Yuhang Zhao,
  Director
• Kevin Smith,
  Director
• Robert DelAversano,
  Principal Accounting Officer, Controller
• Robert Ward,
  Independent Director
• James DeMesa,
  Independent Director
• Joon Kim,
  Director
• Dr. Mai Hope Le M.D.,
  Consultant
• Dr. Sandra Aung Ph.D.,
  Sr. VP & Chief Clinical Devel. Officer
• Tu Diep M.Sc.,
  Sr. VP & Head of Operations
• Dr. Kim Jaffe,
  Assistant VP of Bus. Devel. & Operations
• Robert Hamilton Pierce,
  Chief Medical Officer
• Sheela Mohan Peterson,
  Chief Legal Officer
• Sharron E Gargosky,
  Chief Clinical & Reg. Officer
• Anthony E Iii Maida,
  Director
• Mai Hope Le,
  Chief Medical Officer
• Richard B Slansky,
  Chief Financial Officer
• Avtar S Dhillon,
  Director
• Punit Dhillon,
  President and CEO
• Annalisa Jenkins,
  Director
• Gregory T. Mayes,,
  Director
• Sara Bonstein,
  CFO/COO
• Spahr Stephany Foster,
  Director
• Veronica Vallejo,
  Chief Financial Officer
• Grand Pharmaceutical & Heal...,
  
• Kellie Malloy Foerter,
  Chief Operating Officer
• Holdings, Inc. Alpha,
  Director
• Brian A Leuthner,
  Interim CEO
• Robert H. Arch,
  President and CEO